{
  "input_name": "Novartis",
  "canonical": {
    "resolved_name": "Novartis AG",
    "ticker": "NVS",
    "cik": 1114448.0,
    "website": "https://www.novartis.com",
    "name_variants": [
      "Novartis AG"
    ]
  },
  "pipeline": {
    "candidates": [
      {
        "nct": "NCT04137640",
        "status": "NOT_YET_RECRUITING",
        "phase": "phase4",
        "condition": "Breast Cancer",
        "intervention": "palbociclib combined with letrozole",
        "source_url": "https://clinicaltrials.gov/study/NCT04137640",
        "fetched": "2025-09-24T13:40:27.619873",
        "evidence_snippet": "Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | Condition: Breast Cancer | Interve",
        "matched_variant": "Novartis AG"
      },
      {
        "nct": "NCT06481189",
        "status": "COMPLETED",
        "phase": "phase1",
        "condition": "Healthy Volunteers",
        "intervention": "GNR-086",
        "source_url": "https://clinicaltrials.gov/study/NCT06481189",
        "fetched": "2025-09-24T13:40:27.619873",
        "evidence_snippet": "A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris\u00ae in Healthy Volunteers | Condition: Healthy Volunteers | Intervention: GNR",
        "matched_variant": "Novartis AG"
      },
      {
        "nct": "NCT01377597",
        "status": "COMPLETED",
        "phase": "phase3",
        "condition": "Retinal Vein Occlusion",
        "intervention": "ranibizumab",
        "source_url": "https://clinicaltrials.gov/study/NCT01377597",
        "fetched": "2025-09-24T13:40:27.619873",
        "evidence_snippet": "Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion | Condition: Retinal Vein Occlusion | Intervention: ranibizumab",
        "matched_variant": "Novartis AG"
      },
      {
        "nct": "NCT00719264",
        "status": "COMPLETED",
        "phase": "phase2",
        "condition": "Carcinoma",
        "intervention": "RAD001(everolimus)",
        "source_url": "https://clinicaltrials.gov/study/NCT00719264",
        "fetched": "2025-09-24T13:40:27.619873",
        "evidence_snippet": "Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Ca",
        "matched_variant": "Novartis AG"
      },
      {
        "nct": "NCT00170781",
        "status": "COMPLETED",
        "phase": "phase4",
        "condition": "Acute Gouty Arthritis",
        "intervention": "Lumiracoxib",
        "source_url": "https://clinicaltrials.gov/study/NCT00170781",
        "fetched": "2025-09-24T13:40:27.619873",
        "evidence_snippet": "Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout | Condition: Acute Gouty Arthritis | Intervention: Lumiracoxib",
        "matched_variant": "Novartis AG"
      }
    ],
    "counts_by_phase": {
      "phase4": 2,
      "phase1": 1,
      "phase3": 1,
      "phase2": 1
    }
  },
  "financial": {
    "public": true,
    "filings": [],
    "provenance": []
  },
  "news": []
}